Literature DB >> 16807423

Fondaparinux versus enoxaparin in acute coronary syndromes.

David T Majure, Scott K Aberegg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16807423     DOI： 10.1056/NEJMc061206

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

Review 1.  Cost effectiveness of anticoagulation in acute coronary syndromes.

Authors:  Jaime Latour-Pérez; Eva de-Miguel-Balsa
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

Review 2.  [Myocardial infarct and unstable angina pectoris: diagnostics and therapy].

Authors:  M Weber; C Hamm
Journal:  Internist (Berl)       Date:  2007-04       Impact factor: 0.743

3.  Bleeding after antithrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them?

Authors:  Marc Cohen; Karen P Alexander; Sunil V Rao
Journal:  J Thromb Thrombolysis       Date:  2007-12-15       Impact factor: 2.300

4.  Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data.

Authors:  Alexandre de Matos Soeiro; Pedro Gabriel Melo de Barros E Silva; Eduardo Alberto de Castro Roque; Aline Siqueira Bossa; Maria Cristina César; Sheila Aparecida Simões; Mariana Yumi Okada; Tatiana de Carvalho Andreucci Torres Leal; Fátima Cristina Monteiro Pedroti; Múcio Tavares de Oliveira
Journal:  Arq Bras Cardiol       Date:  2016-08-29       Impact factor: 2.000
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.